• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024

    2/6/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BMY alert in real time by email

    Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth

    • Fourth Quarter Revenues were $12.3 Billion, Increasing 8% (+9% Adjusting for Foreign Exchange); GAAP Earnings Per Share (EPS) was $0.04 and Non-GAAP EPS was $1.67
      • Growth Portfolio Revenues were $6.4 Billion, Increasing 21% (+23% Adjusting for Foreign Exchange)
    • Full-Year Revenues were $48.3 Billion, Increasing 7% (+9% Adjusting for Foreign Exchange); GAAP Loss Per Share was $(4.41) and Non-GAAP EPS was $1.15; Includes Net Impact of $(6.39) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income
      • Growth Portfolio Revenues were $22.6 Billion, Increasing 17% (+19% Adjusting for Foreign Exchange)
    • Achieved Multiple Clinical and Regulatory Milestones in the Fourth Quarter, Including U.S. Approval of Opdivo Qvantig and the U.S. Launch of Cobenfy
    • Expands Strategic Productivity Initiative to Deliver ~$2 Billion in Additional Cost Savings by the End of 2027
    • Provides 2025 Guidance with Revenues of ~$45.5 Billion; Non-GAAP EPS Range of $6.55 to $6.85

    Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2024.

    "We made good progress in 2024, which was capped by a fourth quarter of strong topline growth driven by key products and important pipeline advancements. We also achieved the landmark U.S. approval of Cobenfy last year for the treatment of schizophrenia in adults, and we expect this medicine to have a meaningful impact on patients and the company as a new growth driver," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "Our collective focus on execution has established a solid foundation to navigate the multi-year journey toward achieving top-tier sustainable growth and long-term shareholder returns."

     

    Fourth Quarter

    $ in millions, except per share amounts

    2024

     

    2023

     

    Change

     

    Change

    Excl. F/X**

    Total Revenues

    $12,342

     

    $11,477

     

     

    8%

     

    9%

    Earnings Per Share - GAAP*

    0.04

     

    0.87

     

     

    (95)%

     

    N/A

    Earnings Per Share - Non-GAAP*

    1.67

     

    1.70

     

     

    (2)%

     

    N/A

    Acquired IPRD Charge and Licensing Income Net Impact on Earnings Per Share

    0.01

     

    (0.20

    )

     

    N/A

     

    N/A

    *GAAP and Non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income.

    **See "Use of Non-GAAP Financial Information".

     

    Full Year

    $ in millions, except per share amounts

    2024

     

    2023

     

    Change

     

    Change

    Excl. F/X**

    Total Revenues

    $48,300

     

     

    $45,006

     

     

    7%

     

    9%

    (Loss)/Earnings Per Share - GAAP*

    (4.41

    )

     

    3.86

     

     

    N/A

     

    N/A

    Earnings Per Share - Non-GAAP*

    1.15

     

     

    7.51

     

     

    (85)%

     

    N/A

    Acquired IPRD Charge and Licensing Income Net Impact on Earnings Per Share

    (6.39

    )

     

    (0.28

    )

     

    N/A

     

    N/A

    *GAAP and Non-GAAP earnings per share include the net impact of Acquired IPRD charges and licensing income.

    **See "Use of Non-GAAP Financial Information".

    FOURTH QUARTER RESULTS

    All comparisons are made versus the same period in 2023 unless otherwise stated.

    • Bristol Myers Squibb posted fourth quarter revenues of $12.3 billion, an increase of 8%, or 9% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and higher demand for Eliquis, partially offset by the impact of generics on Sprycel, Revlimid, Abraxane and Pomalyst.
      • U.S. revenues increased 9% to $8.6 billion, primarily driven by higher demand for the Growth Portfolio and Eliquis, partially offset by the impact of generics within the Legacy Portfolio.
      • International revenues increased 5% to $3.7 billion, or 9% when adjusted for foreign exchange impacts, primarily driven by higher demand for the Growth Portfolio, partially offset by the impact of generics within the Legacy Portfolio.
    • On a GAAP basis, gross margin decreased from 76.1% to 61.0%, primarily driven by intangible asset impairment charges and product mix. On a non-GAAP basis, gross margin decreased from 76.4% to 74.0%, primarily due to product mix.
    • On a GAAP and non-GAAP basis, marketing, selling and administrative expenses remained relatively flat at $2.1 billion.
    • On a GAAP basis, research and development expenses increased 29% to $3.2 billion, primarily due to the impact of recent acquisitions and IPRD impairment charges. On a non-GAAP basis, research and development expenses increased 13% to $2.8 billion, primarily due to the impact of recent acquisitions.
    • On a GAAP and non-GAAP basis, Acquired IPRD decreased to $30 million from $600 million. On a GAAP and non-GAAP basis, licensing income was $48 million compared to $67 million.
    • On a GAAP basis, amortization of acquired intangible assets decreased 26% to $1.7 billion, primarily due to lower amortization expense related to Revlimid, partially offset by the RayzeBio acquisition in 2024.
    • On a GAAP basis, the effective tax rate was 56.6%, primarily due to the impact of intangible asset impairments and amortization of acquired intangible assets. In 2023, the income tax benefit was $88 million despite pre-tax earnings of $1.7 billion, primarily due to a valuation allowance reversal and foreign currency. On a non-GAAP basis, the effective tax rate changed from 14.9% to 19.9%, primarily due to jurisdictional earnings mix.
    • On a GAAP basis, the company reported net income attributable to Bristol Myers Squibb of $72 million, or $0.04 per share, during the fourth quarter of 2024 compared to net earnings of $1.8 billion, or $0.87 per share, for the same period a year ago. The company reported non-GAAP net earnings attributable to Bristol Myers Squibb of $3.4 billion, or $1.67 per share, during the fourth quarter of 2024 compared to $3.5 billion, or $1.70 per share, for the same period a year ago.

    FOURTH QUARTER PRODUCT REVENUE HIGHLIGHTS

     

    ($ amounts in millions)

     

    Quarter Ended December

    31, 2024

     

    % Change from Quarter

    Ended December 31,

    2023

     

    % Change from

    Quarter Ended

    December 31,

    2023 Ex-F/X**

     

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    Int'l(c)

     

    WW(d)

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

     

    $

    1,423

     

    $

    1,056

     

    $

    2,479

     

    2%

     

    7%

     

    4%

     

    15%

     

    7%

    Orencia

     

     

    750

     

     

    250

     

     

    1,000

     

    (1)%

     

    9%

     

    2%

     

    15%

     

    3%

    Yervoy

     

     

    428

     

     

    247

     

     

    675

     

    26%

     

    9%

     

    19%

     

    15%

     

    22%

    Reblozyl

     

     

    445

     

     

    102

     

     

    547

     

    65%

     

    104%

     

    71%

     

    110%

     

    72%

    Opdualag

     

     

    233

     

     

    21

     

     

    254

     

    25%

     

    >200%

     

    34%

     

    >200%

     

    34%

    Breyanzi

     

     

    209

     

     

    54

     

     

    263

     

    146%

     

    >200%

     

    160%

     

    >200%

     

    162%

    Camzyos

     

     

    201

     

     

    22

     

     

    223

     

    142%

     

    >200%

     

    153%

     

    >200%

     

    153%

    Zeposia

     

     

    115

     

     

    43

     

     

    158

     

    15%

     

    30%

     

    19%

     

    33%

     

    20%

    Abecma

     

     

    59

     

     

    46

     

     

    105

     

    5%

     

    5%

     

    5%

     

    5%

     

    5%

    Sotyktu

     

     

    64

     

     

    19

     

     

    83

     

    14%

     

    171%

     

    32%

     

    171%

     

    32%

    Krazati

     

     

    36

     

     

    3

     

     

    39

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Augtyro

     

     

    13

     

     

    2

     

     

    15

     

    >200%

     

    N/A

     

    >200%

     

    N/A

     

    >200%

    Cobenfy

     

     

    10

     

     

    —

     

     

    10

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(a)

     

     

    186

     

     

    326

     

     

    512

     

    13%

     

    104%

     

    58%

     

    106%

     

    59%

    Total Growth Portfolio

     

     

    4,172

     

     

    2,191

     

     

    6,363

     

    19%

     

    24%

     

    21%

     

    31%

     

    23%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

     

     

    2,221

     

     

    974

     

     

    3,195

     

    19%

     

    (3)%

     

    11%

     

    (2)%

     

    11%

    Revlimid

     

     

    1,169

     

     

    170

     

     

    1,339

     

    (6)%

     

    (17)%

     

    (8)%

     

    (15)%

     

    (7)%

    Pomalyst/Imnovid

     

     

    685

     

     

    138

     

     

    823

     

    9%

     

    (48)%

     

    (8)%

     

    (47)%

     

    (7)%

    Sprycel

     

     

    135

     

     

    63

     

     

    198

     

    (67)%

     

    (45)%

     

    (62)%

     

    (41)%

     

    (61)%

    Abraxane

     

     

    91

     

     

    83

     

     

    174

     

    (48)%

     

    17%

     

    (30)%

     

    28%

     

    (26)%

    Other Legacy Products(b)

     

     

    123

     

     

    127

     

     

    250

     

    46%

     

    (14)%

     

    8%

     

    (15)%

     

    7%

    Total Legacy Portfolio

     

     

    4,424

     

     

    1,555

     

     

    5,979

     

    —%

     

    (14)%

     

    (4)%

     

    (12)%

     

    (3)%

    Total Revenues

     

    $

    8,596

     

    $

    3,746

     

    $

    12,342

     

    9%

     

    5%

     

    8%

     

    9%

     

    9%

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Includes Nulojix, Onureg, Inrebic, Empliciti and royalty revenue.

    (b)

    Includes other mature brands.

    (c)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (d)

    Worldwide (WW) includes U.S. and International (Int'l).

    FOURTH QUARTER PRODUCT REVENUE HIGHLIGHTS

    Growth Portfolio

    Growth Portfolio worldwide revenues increased to $6.4 billion compared to $5.3 billion in the prior year period, representing growth of 21% on a reported basis, or 23% when adjusted for foreign exchange impacts. Growth Portfolio revenues were primarily due to higher demand for Reblozyl, Breyanzi, Camzyos, Yervoy and Opdualag.

    Legacy Portfolio

    Revenues for the Legacy Portfolio in the fourth quarter were $6.0 billion compared to $6.2 billion in the prior year period, representing a decline of 4% on a reported basis and 3% when adjusted for foreign exchange impacts. Legacy Portfolio revenues were lower primarily due to the impact of generics on Sprycel, Revlimid, Abraxane and Pomalyst, partially offset by higher demand for Eliquis.

    PRODUCT AND PIPELINE UPDATE

    Neuroscience

    Category

    Asset

    Milestone

    Clinical &

    Research

    CobenfyTM (xanomeline and trospium chloride)

    Long-term data from the Phase 3 EMERGENT-4 and EMERGENT-5 trials evaluating Cobenfy in adults with schizophrenia showed that Cobenfy was generally well tolerated over 52 weeks, with continued improvements in symptoms and a side effect profile consistent with prior trials of the treatment in this indication.

    Oncology

    Category

    Asset

    Milestone

    Regulatory

    Opdivo® (nivolumab) + Yervoy® (ipilimumab)

    The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended approval of Opdivo + Yervoy for the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma. The recommendation is based on results of the Phase 3 CheckMate -9DW trial. The CHMP opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union.

     

    AugtyroTM (repotrectinib)*

    The EC approved Augtyro, a next-generation tyrosine kinase inhibitor (TKI), as a treatment for adult patients with ROS1-positive advanced non-small cell lung cancer and for the treatment of adult and pediatric patients 12 years of age and older with advanced solid tumors expressing a NTRK gene fusion, and who have received a prior NTRK inhibitor, or have not received a prior NTRK inhibitor and treatment options not targeting NTRK provide limited clinical benefit, or have been exhausted. The approval is based on results from the TRIDENT-1 and CARE trials.

     

    *Approval received on January 13, 2025, and announced today by the company.

     

    Opdivo QvantigTM (nivolumab and hydaluronidase-nyhy)

    The U.S. Food and Drug Administration (FDA) approved Opdivo Qvantig injection for subcutaneous use in most previously approved adult, solid tumor Opdivo indications as monotherapy, monotherapy maintenance after completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib. The approval is based on results from the Phase 3 randomized, open-label CheckMate -67T trial.

     

    Opdivo + Yervoy

    The EC approved Opdivo plus Yervoy for the first-line treatment of adult patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer (mCRC). The approval is based on results from the CheckMate -8HW trial.

    Clinical &

    Research

    Opdivo + Yervoy

    Results from an analysis of the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy for microsatellite instability-high/mismatch repair-deficient mCRC demonstrated a statistically significant and clinically meaningful improvement at a median follow up of 47 months in the dual primary endpoint of progression-free survival as assessed by Blinded Independent Central Review.

    Hematology

    Category

    Asset

    Milestone

    Clinical &

    Research

    Breyanzi® (lisocabtagene maraleucel)

    Five-year overall survival data from the Phase 1 TRANSCEND NHL 001 study supported deep and durable responses of Breyanzi in patients with relapsed or refractory large B-cell lymphoma (LBCL) with median overall survival (OS) of 27.5 months and an estimated OS rate at five years of 38 percent. Breyanzi continued to demonstrate an established safety profile with no new safety signals.

     

    In addition, new circulating tumor DNA (ctDNA) from the Phase 3 TRANSFORM study supported the superiority of Breyanzi to achieve deeper responses over the former standard of care in second-line LBCL.

    Regulatory

    Breyanzi

    The CHMP of the EMA recommended approval of Breyanzi for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. The recommendation is based on data from the Phase 2 TRANSCEND FL study. The CHMP opinion will now be reviewed by the EC.

    Cardiovascular

    Category

    Asset

    Milestone

    Clinical & Research

    Camzyos® (mavacamten)

    In Europe, following an opinion from the CHMP of the EMA, Camzyos received a label update to reduce the frequency of required echocardiography monitoring once a patient treated for obstructive hypertrophic cardiomyopathy is on a stable dose.

     

    In addition, the company is today announcing the receipt of an April Prescription Drug User Fee Act (PDUFA) goal date from the FDA in the same setting.

    Immunology

    Category

    Asset

    Milestone

    Clinical & Research

    Sotyktu® (deucravacitinib)

    Results from the Phase 3 POETYK PsA-1 and POETYK PsA-2 trials evaluating the efficacy and safety of Sotyktu in adults with active psoriatic arthritis (PsA) met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20 percent improvement in signs and symptoms of disease after 16 weeks of treatment compared with placebo.

     

    In addition, both trials met secondary endpoints across PsA disease activity at Week 16. In both studies, Sotyktu was well-tolerated and demonstrated safety consistent with the established safety profile of Sotyktu observed in a Phase 2 PsA clinical trial and Phase 3 moderate-to-severe plaque psoriasis clinical trials.

    FULL-YEAR FINANCIAL RESULTS

    All comparisons are made versus the same period in 2023 unless otherwise stated.

    • Bristol Myers Squibb posted revenues of $48.3 billion, an increase of 7%, or 9% when adjusted for foreign exchange impacts, primarily driven by the Growth Portfolio and higher demand for Eliquis, partially offset by the impact of generics on Sprycel, Revlimid and Abraxane.
      • U.S. revenues increased 9% to $34.1 billion, primarily due to higher demand for the Growth Portfolio and Eliquis, partially offset by the impact of generics on Sprycel, Revlimid and Abraxane.
      • International revenues increased 3% to $14.2 billion, or 8.0% when adjusted for foreign exchange impacts, primarily due to demand for Growth Portfolio products, partially offset by the impact of generics within the Legacy Portfolio.
    • On a GAAP basis, gross margin decreased from 76.2% to 71.1%, primarily driven by intangible asset impairment charges and product mix. On a non-GAAP basis, gross margin decreased from 76.6% to 75.3%, primarily due to product mix.
    • On a GAAP and non-GAAP basis, marketing, selling and administrative expenses increased 8% to $8.4 billion and 4% to $8.0 billion, respectively. The increase is primarily due to the timing of spend and the impact of recent acquisitions.
    • On a GAAP basis, research and development expenses increased 20% to $11.2 billion, primarily due to the impact of recent acquisitions and IPRD impairment charges. On a non-GAAP basis, research and development expenses increased 7% to $9.8 billion, primarily due to the impact of recent acquisitions.
    • On a GAAP and non-GAAP basis, Acquired IPRD increased from $913 million to $13.4 billion driven by a one-time Acquired IPRD charge from the Karuna asset acquisition and SystImmune collaboration. On a GAAP and non-GAAP basis, licensing income was $122 million during the year compared to $142 million in 2023.
    • On a GAAP basis, amortization of acquired intangible assets decreased 2% to $8.9 billion, primarily due to lower amortization expense related to Revlimid, partially offset by the RayzeBio acquisition in 2024.
    • On a GAAP basis, income tax expense was $554 million despite a pre-tax loss of $8.4 billion, primarily due to a $12.1 billion non-tax deductible charge for the Karuna acquisition. The 2023 GAAP effective tax rate was impacted by a non-U.S. tax ruling on statutory impairment deductibility, changes in tax reserves, valuation allowances, and IRS guidance on non-U.S. R&D expense deductibility. On a non-GAAP basis, the effective tax rate increased from 14.7% to 56.8%, primarily due to the non-tax deductible charge.
    • The company reported on a GAAP basis net loss attributable to Bristol Myers Squibb of $8.9 billion, or $(4.41) per share, compared to earnings attributable to Bristol Myers Squibb of $8.0 billion, or $3.86 per share for the same period a year ago. On a non-GAAP basis the company reported net earnings attributable to Bristol Myers Squibb of $2.3 billion, or $1.15 per share, compared to earnings attributable to Bristol Myers Squibb of $15.6 billion, or $7.51 per share for the same period a year ago. In addition to the non-GAAP drivers noted above, non-GAAP EPS was impacted by higher interest expense.

    FULL-YEAR PRODUCT REVENUE HIGHLIGHTS

     

    ($ amounts in millions)

     

    Year Ended December

    31, 2024

     

    % Change from Year Ended

    December 31, 2023

     

    % Change from

    Year Ended

    December 31,

    2023 Ex-F/X**

     

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    Int'l(c)

     

    WW(d)

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

     

    $

    5,350

     

    $

    3,954

     

    $

    9,304

     

    2%

     

    5%

     

    3%

     

    14%

     

    7%

    Orencia

     

     

    2,770

     

     

    912

     

     

    3,682

     

    2%

     

    2%

     

    2%

     

    10%

     

    4%

    Yervoy

     

     

    1,599

     

     

    931

     

     

    2,530

     

    16%

     

    8%

     

    13%

     

    15%

     

    16%

    Reblozyl

     

     

    1,444

     

     

    329

     

     

    1,773

     

    80%

     

    61%

     

    76%

     

    65%

     

    77%

    Opdualag

     

     

    870

     

     

    58

     

     

    928

     

    41%

     

    >200%

     

    48%

     

    >200%

     

    48%

    Breyanzi

     

     

    591

     

     

    156

     

     

    747

     

    95%

     

    156%

     

    105%

     

    162%

     

    106%

    Camzyos

     

     

    543

     

     

    59

     

     

    602

     

    141%

     

    >200%

     

    161%

     

    >200%

     

    161%

    Zeposia

     

     

    403

     

     

    163

     

     

    566

     

    26%

     

    42%

     

    30%

     

    42%

     

    30%

    Abecma

     

     

    242

     

     

    164

     

     

    406

     

    (32)%

     

    44%

     

    (14)%

     

    47%

     

    (13)%

    Sotyktu

     

     

    190

     

     

    56

     

     

    246

     

    21%

     

    >200%

     

    45%

     

    >200%

     

    46%

    Krazati

     

     

    118

     

     

    8

     

     

    126

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Augtyro

     

     

    36

     

     

    2

     

     

    38

     

    >200%

     

    N/A

     

    >200%

     

    N/A

     

    >200%

    Cobenfy

     

     

    10

     

     

    —

     

     

    10

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(a)

     

     

    674

     

     

    931

     

     

    1,605

     

    9%

     

    58%

     

    33%

     

    61%

     

    34%

    Total Growth Portfolio

     

     

    14,840

     

     

    7,723

     

     

    22,563

     

    17%

     

    16%

     

    17%

     

    24%

     

    19%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

     

     

    9,631

     

     

    3,702

     

     

    13,333

     

    14%

     

    (1)%

     

    9%

     

    —%

     

    9%

    Revlimid

     

     

    4,999

     

     

    774

     

     

    5,773

     

    (4)%

     

    (14)%

     

    (5)%

     

    (11)%

     

    (5)%

    Pomalyst/Imnovid

     

     

    2,695

     

     

    850

     

     

    3,545

     

    15%

     

    (23)%

     

    3%

     

    (22)%

     

    3%

    Sprycel

     

     

    983

     

     

    303

     

     

    1,286

     

    (31)%

     

    (40)%

     

    (33)%

     

    (36)%

     

    (32)%

    Abraxane

     

     

    541

     

     

    334

     

     

    875

     

    (23)%

     

    11%

     

    (13)%

     

    25%

     

    (8)%

    Other Legacy Products(b)

     

     

    416

     

     

    509

     

     

    925

     

    25%

     

    (19)%

     

    (4)%

     

    (18)%

     

    (3)%

    Total Legacy Portfolio

     

     

    19,265

     

     

    6,472

     

     

    25,737

     

    4%

     

    (10)%

     

    —%

     

    (8)%

     

    1%

    Total Revenues

     

    $

    34,105

     

    $

    14,195

     

    $

    48,300

     

    9%

     

    3%

     

    7%

     

    8%

     

    9%

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Includes Nulojix, Onureg, Inrebic, Empliciti and royalty revenue.

    (b)

    Includes other mature brands.

    (c)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (d)

    Worldwide (WW) includes U.S. and International (Int'l).

    FULL-YEAR PRODUCT REVENUE HIGHLIGHTS

    Growth Portfolio

    Growth Portfolio worldwide revenues increased to $22.6 billion compared to $19.4 billion in the prior year period, representing growth of 17% on a reported basis, or 19% when adjusted for foreign exchange impacts. Growth Portfolio revenues were primarily driven by higher demand for Reblozyl, Breyanzi, Camzyos and Opdualag.

    Legacy Portfolio

    Revenues for the Legacy Portfolio remained relatively flat at $25.7 billion compared to $25.6 billion in the prior year period, and increased 1% when adjusted for foreign exchange impacts. Legacy Portfolio revenues were primarily driven by higher demand for Eliquis, offset by the impact of generics on Sprycel, Revlimid, Abraxane and Pomalyst.

    Update on Strategic Productivity Initiative

    Bristol Myers Squibb is expanding its existing strategic productivity initiative to include approximately $2 billion in additional annualized cost savings by the end of 2027.

    Under this expanded initiative, savings will be driven by changes in organizational design and efforts to enhance operational efficiency. These savings will be removed from our cost structure to contribute to a leaner, more efficient company while investing behind growth brands and promising areas of science.

    Financial Guidance

    Bristol Myers Squibb is providing key 2025 non-GAAP line-item guidance assumptions as outlined below.



    We estimate total revenues to be approximately $45.5 billion, reflecting, as previously expected, the near-term impact of generics across Revlimid, Pomalyst, Sprycel and Abraxane, which we expect to result in a revenue decline of approximately 18-20% of the Legacy Portfolio. This is expected to be partially offset by the continued strength of our Growth Portfolio. This guidance also reflects an approximate $500 million expected negative impact to revenue due to foreign exchange.

    2025 Non-GAAP1 Line-Item Guidance

    Total Revenues

    (Reported & Ex-F/X)

    ~$45.5 billion

    Gross Margin %

    ~72%

    Operating Expenses2

    ~$16 billion

    Other Income/(Expense)

    ~$30 million

    Tax Rate

    ~18%

    Diluted EPS

    $6.55-$6.85

    1See "Use of Non-GAAP Financial Information."

    2Operating Expenses = MS&A and R&D, excluding Acquired IPRD and Amortization of acquired intangible assets.

    The 2025 financial guidance excludes the impact of any potential future strategic acquisitions, divestitures, specified items that have not yet been identified and quantified, and the impact of future Acquired IPRD charges. To the extent we have quantified the impact of significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights, we may update this information from time to time on our website www.bms.com, in the "Investors" section. Non-GAAP guidance assumes current exchange rates. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release.

    A reconciliation of forward-looking non-GAAP measures, including non-GAAP EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results. See "Cautionary Statement Regarding Forward-Looking Statements" and "Use of Non-GAAP Financial Information."

    Conference Call Information

    Bristol Myers Squibb will host a conference call today, Thursday, February 6, 2025, at 8:00 a.m. ET, during which company executives will review quarterly and annual financial results and address inquiries from investors and analysts. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com.

    Investors and the public can register for the live conference call here. Those unable to register can access the live conference call by dialing in the U.S. toll-free 1-833-816-1116 or international +1 412-317-0705. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call.

    A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. A replay of the conference call will be available beginning at 11:30 a.m. ET on February 6, 2025, through 11:30 a.m. ET on February 20, 2025, by dialing in the U.S. toll free 1-877-344-7529 or international +1 412-317-0088, confirmation code: 5943651.

    About Bristol Myers Squibb

    Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, X, YouTube, Facebook, and Instagram.

    corporatefinancial-news

    Use of Non-GAAP Financial Information

    In discussing financial results and guidance, the company refers to financial measures that are not in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The non-GAAP financial measures are provided as supplemental information to the financial measures presented in this press release that are calculated and presented in accordance with GAAP and are presented because management has evaluated the company's financial results both including and excluding the adjusted items or the effects of foreign currency translation, as applicable, and believes that the non-GAAP financial measures presented portray the results of the company's baseline performance, supplement or enhance management's, analysts' and investors' overall understanding of the company's underlying financial performance and trends and facilitate comparisons among current, past and future periods. In addition, non-GAAP gross margin, which is gross profit excluding certain specified items, as a percentage of revenues, non-GAAP operating margin, which is gross profit less marketing, selling and administrative expenses and research and development expenses excluding certain specified items as a percentage of revenues, non-GAAP operating expenses, which is marketing, selling and administrative and research and development expenses excluding certain specified items, non-GAAP marketing, selling and administrative expenses, which is marketing, selling and administrative expenses excluding certain specified items, and non-GAAP research and development expenses, which is research and development expenses excluding certain specified items, are relevant and useful for investors because they allow investors to view performance in a manner similar to the method used by our management and make it easier for investors, analysts and peers to compare our operating performance to other companies in our industry and to compare our year-over-year results.

    This earnings release and the accompanying tables also provide certain revenues and expenses, as well as non-GAAP measures, excluding the impact of foreign exchange ("Ex-Fx"). We calculate foreign exchange impacts by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results. Ex-Fx financial measures are not accounted for according to GAAP because they remove the effects of currency movements from GAAP results.

    Non-GAAP financial measures such as non-GAAP earnings and related EPS information are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis after considering their quantitative and qualitative aspects and typically have one or more of the following characteristics, such as being highly variable, difficult to project, unusual in nature, significant to the results of a particular period or not indicative of past or future operating results. These items are excluded from non-GAAP earnings and related EPS information because the company believes they neither relate to the ordinary course of the company's business nor reflect the company's underlying business performance. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwinding of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, costs of acquiring a priority review voucher, divestiture gains or losses, stock compensation resulting from acquisition-related equity awards, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments), income resulting from the change in control of the Nimbus Therapeutics TYK2 Program and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. Deferred and current income taxes attributed to these items are also adjusted for considering their individual impact to the overall tax expense, deductibility and jurisdictional tax rates. Certain other significant tax items are also excluded such as the impact resulting from a non-U.S. tax ruling regarding the deductibility of a statutory impairment of subsidiary investments and release of income tax reserves relating to the Celgene acquisition.

    Because the non-GAAP financial measures are not calculated in accordance with GAAP, they should not be considered superior to and are not intended to be considered in isolation or as a substitute for the related financial measures presented in the press release that are prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. We encourage investors to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

    Reconciliations of the non-GAAP financial measures to the most comparable GAAP measures are provided in the accompanying financial tables and will also be available on the company's website at www.bms.com. Within the accompanying financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and EPS amounts presented are calculated from the underlying amounts.

    A reconciliation of forward-looking non-GAAP measures, including non-GAAP EPS, to the most directly comparable GAAP measures is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Namely, we are not, without unreasonable effort, able to reliably predict the impact of accelerated depreciation and impairment charges, legal and other settlements, gains and losses from equity investments and other adjustments. In addition, the company believes such a reconciliation would imply a degree of precision and certainty that could be confusing to investors. These items are uncertain, depend on various factors and may have a material impact on our future GAAP results.

    Website Information

    We routinely post important information for investors on our website, BMS.com, in the "Investors" section. We may use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investors section of our website, in addition to following our press releases, Securities and Exchange Commission (SEC) filings, public conference calls, presentations and webcasts. We may also use social media channels to communicate with our investors and the public about our company, our products and other matters, and those communications could be deemed to be material information. The information contained on, or that may be accessed through, our website or social media channels are not incorporated by reference into, and are not a part of, this document.

    Cautionary Statement Regarding Forward-Looking Statements

    This earnings release and the related attachments (as well as the oral statements made with respect to information contained in this release and the attachments) contain certain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, the company's 2025 financial guidance, its Strategic Productivity Initiative, its business development and capital allocation strategy, anticipated developments in the company's pipeline, expectations with respect to the company's future market position and the projected benefits of the company's alliances and other business development activities. These statements may be identified by the fact that they use words such as "should," "could," "expect," "anticipate," "estimate," "target," "may," "project," "guidance," "intend," "plan," "believe," "will" and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance, although not all forward-looking statements contain such terms. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. No forward-looking statement can be guaranteed, and there is no assurance that the company will achieve its financial guidance and long-term targets, that the company's future clinical studies will support the data described in this release, that the company's product candidates will receive necessary clinical and manufacturing regulatory approvals, that the company's pipeline products will prove to be commercially successful, that clinical and manufacturing regulatory approvals will be sought or obtained within currently expected timeframes, or that contractual milestones will be achieved.

    Forward-looking statements are based on current expectations and projections about the company's future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond the company's control and could cause the company's future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. Such risks, uncertainties and other matters include, but are not limited to: increasing pricing pressures from market access, pharmaceutical pricing controls and discounting; market actions taken by private and government payers to manage drug utilization and contain costs; the company's ability to retain patent and market exclusivity for certain products; regulatory changes that result in lower prices, lower reimbursement rates and smaller populations for whom payers will reimburse; changes under the 340B Drug Pricing Program; the company's ability to obtain and maintain regulatory approval for its product candidates; the possibility of difficulties and delays in product introduction and commercialization; increasing industry competition; potential difficulties, delays and disruptions in manufacturing, distribution or sale of products; the company's ability to identify potential strategic acquisitions, licensing opportunities or other beneficial transactions; failure to complete, or delays in completing, collaborations, acquisitions, divestitures, alliances and other portfolio actions and the failure to achieve anticipated benefits from such transactions and actions; exposure to litigation and/or regulatory actions or investigations; the impact of any healthcare reform and legislation or regulatory action in the United States and international markets; increasing market penetration of lower-priced generic products; the failure of the company's suppliers, vendors, outsourcing partners, alliance partners and other third parties to meet their contractual, regulatory and other obligations; the impact of counterfeit or unregistered versions of the company's products and from stolen products; product label changes or other measures that could result in declining sales; safety or efficacy concerns regarding the company's products or any product in the same class as the company's products; the risk of cyber-attacks and unauthorized disclosure of trade secrets or other confidential data; the company's ability to execute its financial, strategic and operational plans; the company's ability to attract and retain key personnel; the impact of the company's significant indebtedness; political and financial instability of international economies and sovereign risk; interest rate and currency exchange rate fluctuations, credit and foreign exchange risk management; risks relating to the use of social media platforms; issuance of new or revised accounting standards; and risks relating to public health outbreaks, epidemics and pandemics.

    Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the company's business and market, particularly those identified in the cautionary statement and risk factors discussion in the company's Annual Report on Form 10-K for the year ended December 31, 2023, as updated by the company's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the SEC. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, the company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

    BRISTOL-MYERS SQUIBB COMPANY

    CONSOLIDATED STATEMENTS OF EARNINGS

    (Unaudited, dollars and shares in millions except per share data)

     

     

    Three Months Ended

    December 31,

     

    Twelve Months Ended

    December 31,

     

    2024

     

    2023

     

    2024

     

    2023

     

     

     

     

     

     

     

     

    Net product sales

    $

    11,811

     

     

    $

    11,168

     

     

    $

    46,778

     

     

    $

    43,778

     

    Alliance and other revenues

     

    531

     

     

     

    309

     

     

     

    1,522

     

     

     

    1,228

     

    Total Revenues

     

    12,342

     

     

     

    11,477

     

     

     

    48,300

     

     

     

    45,006

     

     

     

     

     

     

     

     

     

    Cost of products sold(a)

     

    4,812

     

     

     

    2,745

     

     

     

    13,968

     

     

     

    10,693

     

    Marketing, selling and administrative

     

    2,136

     

     

     

    2,073

     

     

     

    8,414

     

     

     

    7,772

     

    Research and development

     

    3,191

     

     

     

    2,478

     

     

     

    11,159

     

     

     

    9,299

     

    Acquired IPRD

     

    30

     

     

     

    600

     

     

     

    13,373

     

     

     

    913

     

    Amortization of acquired intangible assets

     

    1,693

     

     

     

    2,278

     

     

     

    8,872

     

     

     

    9,047

     

    Other (income)/expense, net

     

    305

     

     

     

    (371

    )

     

     

    893

     

     

     

    (1,158

    )

    Total Expenses

     

    12,167

     

     

     

    9,803

     

     

     

    56,679

     

     

     

    36,566

     

     

     

     

     

     

     

     

     

    (Loss)/Earnings Before Income Taxes

     

    175

     

     

     

    1,674

     

     

     

    (8,379

    )

     

     

    8,440

     

    Provision for Income Taxes

     

    99

     

     

     

    (88

    )

     

     

    554

     

     

     

    400

     

    Net (Loss)/Earnings

     

    76

     

     

     

    1,762

     

     

     

    (8,933

    )

     

     

    8,040

     

    Noncontrolling Interest

     

    4

     

     

     

    —

     

     

     

    15

     

     

     

    15

     

    Net (Loss)/Earnings Attributable to BMS

    $

    72

     

     

    $

    1,762

     

     

    $

    (8,948

    )

     

    $

    8,025

     

     

     

     

     

     

     

     

     

    Weighted-Average Common Shares Outstanding:

     

     

     

     

     

     

     

    Basic

     

    2,029

     

     

     

    2,027

     

     

     

    2,027

     

     

     

    2,069

     

    Diluted

     

    2,037

     

     

     

    2,033

     

     

     

    2,027

     

     

     

    2,078

     

     

     

     

     

     

     

     

     

    (Loss)/Earnings per Common Share:

     

     

     

     

     

     

     

    Basic

    $

    0.04

     

     

    $

    0.87

     

     

    $

    (4.41

    )

     

    $

    3.88

     

    Diluted

     

    0.04

     

     

     

    0.87

     

     

     

    (4.41

    )

     

     

    3.86

     

     

     

     

     

     

     

     

     

    Other (income)/expense, net

     

     

     

     

     

     

     

    Interest expense(b)

    $

    496

     

     

    $

    316

     

     

    $

    1,947

     

     

    $

    1,166

     

    Royalty income - divestitures

     

    (284

    )

     

     

    (239

    )

     

     

    (1,104

    )

     

     

    (862

    )

    Royalty and licensing income

     

    (204

    )

     

     

    (420

    )

     

     

    (736

    )

     

     

    (1,488

    )

    Provision for restructuring

     

    77

     

     

     

    44

     

     

     

    635

     

     

     

    365

     

    Investment income

     

    (114

    )

     

     

    (145

    )

     

     

    (478

    )

     

     

    (449

    )

    Integration expenses

     

    70

     

     

     

    62

     

     

     

    284

     

     

     

    242

     

    Litigation and other settlements

     

    13

     

     

     

    3

     

     

     

    84

     

     

     

    (390

    )

    Acquisition expense

     

    —

     

     

     

    32

     

     

     

    50

     

     

     

    32

     

    Intangible asset impairments

     

    —

     

     

     

    —

     

     

     

    47

     

     

     

    29

     

    Equity investment (gains)/losses

     

    205

     

     

     

    (53

    )

     

     

    (16

    )

     

     

    160

     

    Divestiture losses

     

    10

     

     

     

    —

     

     

     

    15

     

     

     

    —

     

    Other

     

    36

     

     

     

    29

     

     

     

    165

     

     

     

    37

     

    Other (income)/expense, net

    $

    305

     

     

    $

    (371

    )

     

    $

    893

     

     

    $

    (1,158

    )

    (a) Excludes amortization of acquired intangible assets.

    (b) Includes amortization of purchase price adjustments to Celgene debt.

    BRISTOL-MYERS SQUIBB COMPANY

    PRODUCT REVENUES

    FOR THE THREE MONTHS ENDED DECEMBER 31, 2024 AND 2023

    (Unaudited, dollars in millions)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Change vs. 2023

     

     

    2024

     

    2023

     

    GAAP

     

    Excl. F/X**

     

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

     

    $

    1,423

     

    $

    1,056

     

    $

    2,479

     

    $

    1,401

     

    $

    986

     

    $

    2,387

     

    2%

     

    7%

     

    4%

     

    2%

     

    15%

     

    7%

    Orencia

     

     

    750

     

     

    250

     

     

    1,000

     

     

    755

     

     

    230

     

     

    985

     

    (1)%

     

    9%

     

    2%

     

    (1)%

     

    15%

     

    3%

    Yervoy

     

     

    428

     

     

    247

     

     

    675

     

     

    340

     

     

    226

     

     

    566

     

    26%

     

    9%

     

    19%

     

    26%

     

    15%

     

    22%

    Reblozyl

     

     

    445

     

     

    102

     

     

    547

     

     

    270

     

     

    50

     

     

    320

     

    65%

     

    104%

     

    71%

     

    65%

     

    110%

     

    72%

    Opdualag

     

     

    233

     

     

    21

     

     

    254

     

     

    186

     

     

    4

     

     

    190

     

    25%

     

    >200%

     

    34%

     

    25%

     

    >200%

     

    34%

    Breyanzi

     

     

    209

     

     

    54

     

     

    263

     

     

    85

     

     

    16

     

     

    101

     

    146%

     

    >200%

     

    160%

     

    146%

     

    >200%

     

    162%

    Camzyos

     

     

    201

     

     

    22

     

     

    223

     

     

    83

     

     

    5

     

     

    88

     

    142%

     

    >200%

     

    153%

     

    142%

     

    >200%

     

    153%

    Zeposia

     

     

    115

     

     

    43

     

     

    158

     

     

    100

     

     

    33

     

     

    133

     

    15%

     

    30%

     

    19%

     

    15%

     

    33%

     

    20%

    Abecma

     

     

    59

     

     

    46

     

     

    105

     

     

    56

     

     

    44

     

     

    100

     

    5%

     

    5%

     

    5%

     

    5%

     

    5%

     

    5%

    Sotyktu

     

     

    64

     

     

    19

     

     

    83

     

     

    56

     

     

    7

     

     

    63

     

    14%

     

    171%

     

    32%

     

    14%

     

    171%

     

    32%

    Krazati

     

     

    36

     

     

    3

     

     

    39

     

     

    —

     

     

    —

     

     

    —

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Augtyro

     

     

    13

     

     

    2

     

     

    15

     

     

    1

     

     

    —

     

     

    1

     

    >200%

     

    N/A

     

    >200%

     

    >200%

     

    N/A

     

    >200%

    Cobenfy

     

     

    10

     

     

    —

     

     

    10

     

     

    —

     

     

    —

     

     

    —

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(a)

     

     

    186

     

     

    326

     

     

    512

     

     

    165

     

     

    160

     

     

    325

     

    13%

     

    104%

     

    58%

     

    13%

     

    106%

     

    59%

    Total Growth Portfolio

     

     

    4,172

     

     

    2,191

     

     

    6,363

     

     

    3,498

     

     

    1,761

     

     

    5,259

     

    19%

     

    24%

     

    21%

     

    19%

     

    31%

     

    23%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

     

     

    2,221

     

     

    974

     

     

    3,195

     

     

    1,872

     

     

    1,002

     

     

    2,874

     

    19%

     

    (3)%

     

    11%

     

    19%

     

    (2)%

     

    11%

    Revlimid

     

     

    1,169

     

     

    170

     

     

    1,339

     

     

    1,244

     

     

    206

     

     

    1,450

     

    (6)%

     

    (17)%

     

    (8)%

     

    (6)%

     

    (15)%

     

    (7)%

    Pomalyst/Imnovid

     

     

    685

     

     

    138

     

     

    823

     

     

    627

     

     

    263

     

     

    890

     

    9%

     

    (48)%

     

    (8)%

     

    9%

     

    (47)%

     

    (7)%

    Sprycel

     

     

    135

     

     

    63

     

     

    198

     

     

    411

     

     

    115

     

     

    526

     

    (67)%

     

    (45)%

     

    (62)%

     

    (67)%

     

    (41)%

     

    (61)%

    Abraxane

     

     

    91

     

     

    83

     

     

    174

     

     

    176

     

     

    71

     

     

    247

     

    (48)%

     

    17%

     

    (30)%

     

    (48)%

     

    28%

     

    (26)%

    Other Legacy Products(b)

     

     

    123

     

     

    127

     

     

    250

     

     

    84

     

     

    147

     

     

    231

     

    46%

     

    (14)%

     

    8%

     

    46%

     

    (15)%

     

    7%

    Total Legacy Portfolio

     

     

    4,424

     

     

    1,555

     

     

    5,979

     

     

    4,414

     

     

    1,804

     

     

    6,218

     

    —%

     

    (14)%

     

    (4)%

     

    —%

     

    (12)%

     

    (3)%

    Total Revenues

     

    $

    8,596

     

    $

    3,746

     

    $

    12,342

     

    $

    7,912

     

    $

    3,565

     

    $

    11,477

     

    9%

     

    5%

     

    8%

     

    9%

     

    9%

     

    9%

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.

    (b)

    Includes other mature brands.

    (c)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (d)

    Worldwide (WW) includes U.S. and International (Int'l).

    BRISTOL-MYERS SQUIBB COMPANY

    PRODUCT REVENUES

    FOR THE TWELVE MONTHS ENDED DECEMBER 31, 2024 AND 2023

    (Unaudited, dollars in millions)

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Change vs. 2023

     

     

    2024

     

    2023

     

    GAAP

     

    Excl. F/X**

     

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

     

    U.S.

     

    Int'l(c)

     

    WW(d)

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

     

    $

    5,350

     

    $

    3,954

     

    $

    9,304

     

    $

    5,246

     

    $

    3,763

     

    $

    9,009

     

    2%

     

    5%

     

    3%

     

    2%

     

    14%

     

    7%

    Orencia

     

     

    2,770

     

     

    912

     

     

    3,682

     

     

    2,709

     

     

    892

     

     

    3,601

     

    2%

     

    2%

     

    2%

     

    2%

     

    10%

     

    4%

    Yervoy

     

     

    1,599

     

     

    931

     

     

    2,530

     

     

    1,379

     

     

    859

     

     

    2,238

     

    16%

     

    8%

     

    13%

     

    16%

     

    15%

     

    16%

    Reblozyl

     

     

    1,444

     

     

    329

     

     

    1,773

     

     

    804

     

     

    204

     

     

    1,008

     

    80%

     

    61%

     

    76%

     

    80%

     

    65%

     

    77%

    Opdualag

     

     

    870

     

     

    58

     

     

    928

     

     

    615

     

     

    12

     

     

    627

     

    41%

     

    >200%

     

    48%

     

    41%

     

    >200%

     

    48%

    Breyanzi

     

     

    591

     

     

    156

     

     

    747

     

     

    303

     

     

    61

     

     

    364

     

    95%

     

    156%

     

    105%

     

    95%

     

    162%

     

    106%

    Camzyos

     

     

    543

     

     

    59

     

     

    602

     

     

    225

     

     

    6

     

     

    231

     

    141%

     

    >200%

     

    161%

     

    141%

     

    >200%

     

    161%

    Zeposia

     

     

    403

     

     

    163

     

     

    566

     

     

    319

     

     

    115

     

     

    434

     

    26%

     

    42%

     

    30%

     

    26%

     

    42%

     

    30%

    Abecma

     

     

    242

     

     

    164

     

     

    406

     

     

    358

     

     

    114

     

     

    472

     

    (32)%

     

    44%

     

    (14)%

     

    (32)%

     

    47%

     

    (13)%

    Sotyktu

     

     

    190

     

     

    56

     

     

    246

     

     

    157

     

     

    13

     

     

    170

     

    21%

     

    >200%

     

    45%

     

    21%

     

    >200%

     

    46%

    Krazati

     

     

    118

     

     

    8

     

     

    126

     

     

    —

     

     

    —

     

     

    —

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Augtyro

     

     

    36

     

     

    2

     

     

    38

     

     

    1

     

     

    —

     

     

    1

     

    >200%

     

    N/A

     

    >200%

     

    >200%

     

    N/A

     

    >200%

    Cobenfy

     

     

    10

     

     

    —

     

     

    10

     

     

    —

     

     

    —

     

     

    —

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(a)

     

     

    674

     

     

    931

     

     

    1,605

     

     

    620

     

     

    591

     

     

    1,211

     

    9%

     

    58%

     

    33%

     

    9%

     

    61%

     

    34%

    Total Growth Portfolio

     

     

    14,840

     

     

    7,723

     

     

    22,563

     

     

    12,736

     

     

    6,630

     

     

    19,366

     

    17%

     

    16%

     

    17%

     

    17%

     

    24%

     

    19%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

     

     

    9,631

     

     

    3,702

     

     

    13,333

     

     

    8,482

     

     

    3,724

     

     

    12,206

     

    14%

     

    (1)%

     

    9%

     

    14%

     

    —%

     

    9%

    Revlimid

     

     

    4,999

     

     

    774

     

     

    5,773

     

     

    5,195

     

     

    902

     

     

    6,097

     

    (4)%

     

    (14)%

     

    (5)%

     

    (4)%

     

    (11)%

     

    (5)%

    Pomalyst/Imnovid

     

     

    2,695

     

     

    850

     

     

    3,545

     

     

    2,339

     

     

    1,102

     

     

    3,441

     

    15%

     

    (23)%

     

    3%

     

    15%

     

    (22)%

     

    3%

    Sprycel

     

     

    983

     

     

    303

     

     

    1,286

     

     

    1,422

     

     

    508

     

     

    1,930

     

    (31)%

     

    (40)%

     

    (33)%

     

    (31)%

     

    (36)%

     

    (32)%

    Abraxane

     

     

    541

     

     

    334

     

     

    875

     

     

    702

     

     

    302

     

     

    1,004

     

    (23)%

     

    11%

     

    (13)%

     

    (23)%

     

    25%

     

    (8)%

    Other Legacy Products(b)

     

     

    416

     

     

    509

     

     

    925

     

     

    334

     

     

    628

     

     

    962

     

    25%

     

    (19)%

     

    (4)%

     

    25%

     

    (18)%

     

    (3)%

    Total Legacy Portfolio

     

     

    19,265

     

     

    6,472

     

     

    25,737

     

     

    18,474

     

     

    7,166

     

     

    25,640

     

    4%

     

    (10)%

     

    —%

     

    4%

     

    (8)%

     

    1%

    Total Revenues

     

    $

    34,105

     

    $

    14,195

     

    $

    48,300

     

    $

    31,210

     

    $

    13,796

     

    $

    45,006

     

    9%

     

    3%

     

    7%

     

    9%

     

    8%

     

    9%

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Includes Onureg, Inrebic, Nulojix, Empliciti and royalty revenues.

    (b)

    Includes other mature brands.

    (c)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (d)

    Worldwide (WW) includes U.S. and International (Int'l).

    BRISTOL-MYERS SQUIBB COMPANY

    INTERNATIONAL REVENUES(a)

    FOREIGN EXCHANGE IMPACT (%)

    (Unaudited)

     

     

    Three Months Ended December 31, 2024

     

    Twelve Months Ended December 31, 2024

     

    Revenue

    Change %

     

    F/X %

    Favorable/

    (Unfavorable)

    **

     

    Revenue

    Change %

    Ex- F/X **

     

    Revenue

    Change %

     

    F/X %

    Favorable/

    (Unfavorable)

    **

     

    Revenue

    Change %

    Ex- F/X **

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

    7%

     

    (8)%

     

    15%

     

    5%

     

    (9)%

     

    14%

    Orencia

    9%

     

    (6)%

     

    15%

     

    2%

     

    (8)%

     

    10%

    Yervoy

    9%

     

    (6)%

     

    15%

     

    8%

     

    (7)%

     

    15%

    Reblozyl

    104%

     

    (6)%

     

    110%

     

    61%

     

    (4)%

     

    65%

    Opdualag

    >200%

     

    NM

     

    >200%

     

    >200%

     

    NM

     

    >200%

    Breyanzi

    >200%

     

    NM

     

    >200%

     

    156%

     

    (6)%

     

    162%

    Camzyos

    >200%

     

    NM

     

    >200%

     

    >200%

     

    NM

     

    >200%

    Zeposia

    30%

     

    (3)%

     

    33%

     

    42%

     

    —%

     

    42%

    Abecma

    5%

     

    —%

     

    5%

     

    44%

     

    (3)%

     

    47%

    Sotyktu

    171%

     

    —%

     

    171%

     

    >200%

     

    NM

     

    >200%

    Krazati

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Augtyro

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Cobenfy

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(b)

    104%

     

    (2)%

     

    106%

     

    58%

     

    (3)%

     

    61%

    Total Growth Portfolio

    24%

     

    (7)%

     

    31%

     

    16%

     

    (8)%

     

    24%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

    (3)%

     

    (1)%

     

    (2)%

     

    (1)%

     

    (1)%

     

    —%

    Revlimid

    (17)%

     

    (2)%

     

    (15)%

     

    (14)%

     

    (3)%

     

    (11)%

    Pomalyst/Imnovid

    (48)%

     

    (1)%

     

    (47)%

     

    (23)%

     

    (1)%

     

    (22)%

    Sprycel

    (45)%

     

    (4)%

     

    (41)%

     

    (40)%

     

    (4)%

     

    (36)%

    Abraxane

    17%

     

    (11)%

     

    28%

     

    11%

     

    (14)%

     

    25%

    Other Legacy Products(c)

    (14)%

     

    1%

     

    (15)%

     

    (19)%

     

    (1)%

     

    (18)%

    Total Legacy Portfolio

    (14)%

     

    (2)%

     

    (12)%

     

    (10)%

     

    (2)%

     

    (8)%

    Total Revenues

    5%

     

    (4)%

     

    9%

     

    3%

     

    (5)%

     

    8%

    NM

    Not meaningful

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Beginning in 2024, Puerto Rico revenues are included in International revenues. Prior period amounts have been reclassified to conform to the current presentation.

    (b)

    Includes Onureg, Nulojix, Empliciti and royalty revenues.

    (c)

    Includes other mature brands.

    BRISTOL-MYERS SQUIBB COMPANY

    WORLDWIDE REVENUES(a)

    FOREIGN EXCHANGE IMPACT (%)

    (Unaudited)

     

     

    Three Months Ended December 31, 2024

     

    Twelve Months Ended December 31, 2024

     

    Revenue

    Change %

     

    F/X %

    Favorable/

    (Unfavorable)

    **

     

    Revenue

    Change % Ex-

    F/X **

     

    Revenue

    Change %

     

    F/X %

    Favorable/

    (Unfavorable)

    **

     

    Revenue

    Change % Ex-

    F/X **

    Growth Portfolio

     

     

     

     

     

     

     

     

     

     

     

    Opdivo

    4%

     

    (3)%

     

    7%

     

    3%

     

    (4)%

     

    7%

    Orencia

    2%

     

    (1)%

     

    3%

     

    2%

     

    (2)%

     

    4%

    Yervoy

    19%

     

    (3)%

     

    22%

     

    13%

     

    (3)%

     

    16%

    Reblozyl

    71%

     

    (1)%

     

    72%

     

    76%

     

    (1)%

     

    77%

    Opdualag

    34%

     

    —%

     

    34%

     

    48%

     

    —%

     

    48%

    Breyanzi

    160%

     

    (2)%

     

    162%

     

    105%

     

    (1)%

     

    106%

    Camzyos

    153%

     

    —%

     

    153%

     

    161%

     

    —%

     

    161%

    Zeposia

    19%

     

    (1)%

     

    20%

     

    30%

     

    —%

     

    30%

    Abecma

    5%

     

    —%

     

    5%

     

    (14)%

     

    (1)%

     

    (13)%

    Sotyktu

    32%

     

    —%

     

    32%

     

    45%

     

    (1)%

     

    46%

    Krazati

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Augtyro

    >200%

     

    NM

     

    >200%

     

    >200%

     

    NM

     

    >200%

    Cobenfy

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

     

    N/A

    Other Growth Products(b)

    58%

     

    (1)%

     

    59%

     

    33%

     

    (1)%

     

    34%

    Total Growth Portfolio

    21%

     

    (2)%

     

    23%

     

    17%

     

    (2)%

     

    19%

    Legacy Portfolio

     

     

     

     

     

     

     

     

     

     

     

    Eliquis

    11%

     

    —%

     

    11%

     

    9%

     

    —%

     

    9%

    Revlimid

    (8)%

     

    (1)%

     

    (7)%

     

    (5)%

     

    —%

     

    (5)%

    Pomalyst/Imnovid

    (8)%

     

    (1)%

     

    (7)%

     

    3%

     

    —%

     

    3%

    Sprycel

    (62)%

     

    (1)%

     

    (61)%

     

    (33)%

     

    (1)%

     

    (32)%

    Abraxane

    (30)%

     

    (4)%

     

    (26)%

     

    (13)%

     

    (5)%

     

    (8)%

    Other Legacy Products(c)

    8%

     

    1%

     

    7%

     

    (4)%

     

    (1)%

     

    (3)%

    Total Legacy Portfolio

    (4)%

     

    (1)%

     

    (3)%

     

    —%

     

    (1)%

     

    1%

    Total Revenues

    8%

     

    (1)%

     

    9%

     

    7%

     

    (2)%

     

    9%

    NM

    Not meaningful

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Worldwide (WW) includes U.S. and International (Int'l).

    (b)

    Includes Onureg, Nulojix, Empliciti and royalty revenues.

    (c)

    Includes other mature brands.

    BRISTOL-MYERS SQUIBB COMPANY

    RECONCILIATION OF GAAP AND NON-GAAP GROWTH DOLLARS AND PERCENTAGES EXCLUDING FOREIGN EXCHANGE IMPACT *

    (Unaudited, dollars in millions)

     

    THREE MONTHS

     

    2024

     

    2023

     

    Change $

     

    Change %

     

    Favorable /

    (Unfavorable)

    F/X $ **

     

    2024

    Excl. F/X

    **

     

    Favorable /

    (Unfavorable)

    F/X % **

     

    % Change

    Excl. F/X

    **

    Revenues

     

    $

    12,342

     

     

    $

    11,477

     

     

    $

    865

     

     

    8

    %

     

    $

    (142)

     

    $

    12,484

     

    (1)%

     

    9%

    Gross profit

     

     

    7,530

     

     

     

    8,732

     

     

     

    (1,202

    )

     

    (14

    )%

     

     

    N/A

     

     

    N/A

     

    N/A

     

    N/A

    Gross profit excluding specified items(a)

     

     

    9,130

     

     

     

    8,770

     

     

     

    360

     

     

    4

    %

     

     

    N/A

     

     

    N/A

     

    N/A

     

    N/A

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin(b)

     

     

    61.0

    %

     

     

    76.1

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin excluding specified items

     

     

    74.0

    %

     

     

    76.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Marketing, selling and administrative

     

     

    2,136

     

     

     

    2,073

     

     

     

    63

     

     

    3

    %

     

     

    21

     

     

    2,157

     

    1%

     

    4%

    Marketing, selling and administrative excluding specified items(a)

     

     

    2,105

     

     

     

    2,064

     

     

     

    41

     

     

    2

    %

     

     

    21

     

     

    2,126

     

    1%

     

    3%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    3,191

     

     

     

    2,478

     

     

     

    713

     

     

    29

    %

     

     

    8

     

     

    3,199

     

    —%

     

    29%

    Research and development excluding specified items(a)

     

     

    2,788

     

     

     

    2,476

     

     

     

    312

     

     

    13

    %

     

     

    8

     

     

    2,796

     

    —%

     

    13%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin(c)

     

     

    17.8

    %

     

     

    36.4

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin excluding specified items

     

     

    34.3

    %

     

     

    36.9

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    TWELVE MONTHS

     

    2024

     

    2023

     

    Change $

     

    Change %

     

    Favorable /

    (Unfavorable) F/X $ **

     

    2024

    Excl. F/X **

     

    Favorable / (Unfavorable) F/X % **

     

    % Change Excl. F/X

    **

    Revenues

     

    $

    48,300

     

     

    $

    45,006

     

     

    $

    3,294

     

     

    7

    %

     

    $

    (654)

     

    $

    48,954

     

    (2)%

     

    9%

    Gross profit

     

     

    34,332

     

     

     

    34,313

     

     

     

    19

     

     

    —

    %

     

     

    N/A

     

     

    N/A

     

    N/A

     

    N/A

    Gross profit excluding specified items(a)

     

     

    36,351

     

     

     

    34,488

     

     

     

    1,863

     

     

    5

    %

     

     

    N/A

     

     

    N/A

     

    N/A

     

    N/A

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin(b)

     

     

    71.1

    %

     

     

    76.2

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Gross margin excluding specified items

     

     

    75.3

    %

     

     

    76.6

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Marketing, selling and administrative

     

     

    8,414

     

     

     

    7,772

     

     

     

    642

     

     

    8

    %

     

     

    89

     

     

    8,503

     

    1%

     

    9%

    Marketing, selling and administrative excluding specified items(a)

     

     

    7,992

     

     

     

    7,678

     

     

     

    314

     

     

    4

    %

     

     

    89

     

     

    8,081

     

    1%

     

    5%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Research and development

     

     

    11,159

     

     

     

    9,299

     

     

     

    1,860

     

     

    20

    %

     

     

    40

     

     

    11,199

     

    —%

     

    20%

    Research and development excluding specified items(a)

     

     

    9,782

     

     

     

    9,112

     

     

     

    670

     

     

    7

    %

     

     

    40

     

     

    9,822

     

    1%

     

    8%

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin(c)

     

     

    30.6

    %

     

     

    38.3

    %

     

     

     

     

     

     

     

     

     

     

     

     

    Operating margin excluding specified items

     

     

    38.5

    %

     

     

    39.3

    %

     

     

     

     

     

     

     

     

     

     

     

     

    *

    Foreign exchange impacts were derived by converting our current-period local currency financial results using the prior period average currency rates and comparing these adjusted amounts to our current-period results.

    **

    See "Use of Non-GAAP Financial Information".

    (a)

    Refer to the Specified Items schedule below for further details.

    (b)

    Represents gross profit as a percentage of Revenues.

    (c)

    Operating margin represents gross profit less marketing, selling and administrative expenses and research and development expenses, as a percentage of Revenues.

    BRISTOL-MYERS SQUIBB COMPANY

    SPECIFIED ITEMS

    (Unaudited, dollars in millions)

     

     

    Three Months Ended

    December 31,

     

    Twelve Months

    Ended December

    31,

     

    2024

     

    2023

     

    2024

     

    2023

    Inventory purchase price accounting adjustments

    $

    13

     

     

    $

    —

     

     

    $

    47

     

     

    $

    84

     

    Intangible asset impairment

     

    1,559

     

     

     

    27

     

     

     

    1,839

     

     

     

    27

     

    Site exit and other costs

     

    28

     

     

     

    11

     

     

     

    133

     

     

     

    64

     

    Cost of products sold

     

    1,600

     

     

     

    38

     

     

     

    2,019

     

     

     

    175

     

     

     

     

     

     

     

     

     

    Acquisition related charges(a)

     

    —

     

     

     

    —

     

     

     

    372

     

     

     

    —

     

    Site exit and other costs

     

    31

     

     

     

    9

     

     

     

    50

     

     

     

    94

     

    Marketing, selling and administrative

     

    31

     

     

     

    9

     

     

     

    422

     

     

     

    94

     

     

     

     

     

     

     

     

     

    IPRD impairments

     

    390

     

     

     

    —

     

     

     

    980

     

     

     

    80

     

    Priority review voucher

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    95

     

    Acquisition related charges(a)

     

    —

     

     

     

    —

     

     

     

    348

     

     

     

    —

     

    Site exit and other costs

     

    13

     

     

     

    2

     

     

     

    49

     

     

     

    12

     

    Research and development

     

    403

     

     

     

    2

     

     

     

    1,377

     

     

     

    187

     

     

     

     

     

     

     

     

     

    Amortization of acquired intangible assets

     

    1,693

     

     

     

    2,278

     

     

     

    8,872

     

     

     

    9,047

     

     

     

     

     

     

     

     

     

    Interest expense(b)

     

    (12

    )

     

     

    (13

    )

     

     

    (49

    )

     

     

    (52

    )

    Equity investment (gain)/losses

     

    204

     

     

     

    (54

    )

     

     

    (18

    )

     

     

    152

     

    Acquisition expenses

     

    —

     

     

     

    32

     

     

     

    50

     

     

     

    32

     

    Integration expenses

     

    70

     

     

     

    62

     

     

     

    284

     

     

     

    242

     

    Divestiture losses

     

    10

     

     

     

    —

     

     

     

    15

     

     

     

    —

     

    Litigation and other settlements

     

    —

     

     

     

    —

     

     

     

    61

     

     

     

    (397

    )

    Provision for restructuring

     

    77

     

     

     

    44

     

     

     

    635

     

     

     

    365

     

    Intangible asset impairment

     

    —

     

     

     

    —

     

     

     

    47

     

     

     

    29

     

    Other

     

    9

     

     

     

    —

     

     

     

    120

     

     

     

    (6

    )

    Other (income)/expense, net

     

    358

     

     

     

    71

     

     

     

    1,145

     

     

     

    365

     

     

     

     

     

     

     

     

     

    Increase to Earnings before income taxes

     

    4,085

     

     

     

    2,398

     

     

     

    13,835

     

     

     

    9,868

     

     

     

     

     

     

     

     

     

    Income taxes on items above

     

    (749

    )

     

     

    (695

    )

     

     

    (2,045

    )

     

     

    (1,639

    )

    Income tax reserve releases

     

    —

     

     

     

    —

     

     

     

    (502

    )

     

     

    —

     

    Income taxes attributed to a non-U.S. tax ruling

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    (656

    )

    Income taxes

     

    (749

    )

     

     

    (695

    )

     

     

    (2,547

    )

     

     

    (2,295

    )

     

     

     

     

     

     

     

     

    Increase to net earnings

    $

    3,336

     

     

    $

    1,703

     

     

    $

    11,288

     

     

    $

    7,573

     

    (a)

    Includes cash settlement of unvested stock awards, and other related costs incurred in connection with the recent acquisitions of Karuna, RayzeBio and Mirati.

    (b)

    Includes amortization of purchase price adjustments to Celgene debt.

     

    BRISTOL-MYERS SQUIBB COMPANY

    RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS

    (Unaudited, dollars and shares in millions except per share data)

     

     

    Three Months Ended December 31,

    2024

     

    Twelve Months Ended December 31,

    2024

     

    GAAP

     

    Specified

    Items(a)

     

    Non-GAAP

     

    GAAP

     

    Specified

    Items(a)

     

    Non-GAAP

    Gross profit

    $

    7,530

     

     

    $

    1,600

     

     

    $

    9,130

     

     

    $

    34,332

     

     

    $

    2,019

     

     

    $

    36,351

     

    Marketing, selling and administrative

     

    2,136

     

     

     

    (31

    )

     

     

    2,105

     

     

     

    8,414

     

     

     

    (422

    )

     

     

    7,992

     

    Research and development

     

    3,191

     

     

     

    (403

    )

     

     

    2,788

     

     

     

    11,159

     

     

     

    (1,377

    )

     

     

    9,782

     

    Amortization of acquired intangible assets

     

    1,693

     

     

     

    (1,693

    )

     

     

    —

     

     

     

    8,872

     

     

     

    (8,872

    )

     

     

    —

     

    Other (income)/expense, net

     

    305

     

     

     

    (358

    )

     

     

    (53

    )

     

     

    893

     

     

     

    (1,145

    )

     

     

    (252

    )

    Earnings/(Loss) before income taxes

     

    175

     

     

     

    4,085

     

     

     

    4,260

     

     

     

    (8,379

    )

     

     

    13,835

     

     

     

    5,456

     

    Provision for income taxes

     

    99

     

     

     

    749

     

     

     

    848

     

     

     

    554

     

     

     

    2,547

     

     

     

    3,101

     

    Net earnings/(loss) attributable to BMS used for diluted EPS calculation

    $

    72

     

     

    $

    3,336

     

     

    $

    3,408

     

     

    $

    (8,948

    )

     

    $

    11,288

     

     

    $

    2,340

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding—diluted

     

    2,037

     

     

     

    2,037

     

     

     

    2,037

     

     

     

    2,027

     

     

     

    2,032

     

     

     

    2,032

     

    Diluted earnings/(loss) per share

    $

    0.04

     

     

    $

    1.63

     

     

    $

    1.67

     

     

    $

    (4.41

    )

     

    $

    5.56

     

     

    $

    1.15

     

     

     

     

     

     

     

     

     

     

     

     

     

    Effective tax rate

     

    56.6

    %

     

     

    (36.7

    )%

     

     

    19.9

    %

     

     

    (6.6

    )%

     

     

    63.4

    %

     

     

    56.8

    %

     

     

     

     

     

     

     

     

     

     

     

     

     

    Three Months Ended December 31,

    2023

     

    Twelve Months Ended December 31,

    2023

     

    GAAP

     

    Specified

    Items(a)

     

    Non-GAAP

     

    GAAP

     

    Specified

    Items(a)

     

    Non-GAAP

    Gross profit

    $

    8,732

     

     

    $

    38

     

     

    $

    8,770

     

     

    $

    34,313

     

     

    $

    175

     

     

    $

    34,488

     

    Marketing, selling and administrative

     

    2,073

     

     

     

    (9

    )

     

     

    2,064

     

     

     

    7,772

     

     

     

    (94

    )

     

     

    7,678

     

    Research and development

     

    2,478

     

     

     

    (2

    )

     

     

    2,476

     

     

     

    9,299

     

     

     

    (187

    )

     

     

    9,112

     

    Amortization of acquired intangible assets

     

    2,278

     

     

     

    (2,278

    )

     

     

    —

     

     

     

    9,047

     

     

     

    (9,047

    )

     

     

    —

     

    Other (income)/expense, net

     

    (371

    )

     

     

    (71

    )

     

     

    (442

    )

     

     

    (1,158

    )

     

     

    (365

    )

     

     

    (1,523

    )

    Earnings before income taxes

     

    1,674

     

     

     

    2,398

     

     

     

    4,072

     

     

     

    8,440

     

     

     

    9,868

     

     

     

    18,308

     

    Provision for income taxes

     

    (88

    )

     

     

    695

     

     

     

    607

     

     

     

    400

     

     

     

    2,295

     

     

     

    2,695

     

    Net earnings attributable to BMS used for diluted EPS calculation

    $

    1,762

     

     

    $

    1,703

     

     

    $

    3,465

     

     

    $

    8,025

     

     

    $

    7,573

     

     

    $

    15,598

     

     

     

     

     

     

     

     

     

     

     

     

     

    Weighted-average common shares outstanding—diluted

     

    2,033

     

     

     

    2,033

     

     

     

    2,033

     

     

     

    2,078

     

     

     

    2,078

     

     

     

    2,078

     

    Diluted earnings per share

    $

    0.87

     

     

    $

    0.83

     

     

    $

    1.70

     

     

    $

    3.86

     

     

    $

    3.65

     

     

    $

    7.51

     

     

     

     

     

     

     

     

     

     

     

     

     

    Effective tax rate

     

    (5.3

    )%

     

     

    20.2

    %

     

     

    14.9

    %

     

     

    4.7

    %

     

     

    10.0

    %

     

     

    14.7

    %

    (a) Refer to the Specified Items schedule above for further details. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate.

    BRISTOL-MYERS SQUIBB COMPANY

    NET DEBT CALCULATION

    AS OF DECEMBER 31, 2024 AND DECEMBER 31, 2023

    (Unaudited, dollars in millions)

     

     

     

     

     

    December 31,

    2024

     

    December 31,

    2023

     

     

     

     

    Cash and cash equivalents

    $

    10,346

     

     

    $

    11,464

     

    Marketable debt securities - current

     

    513

     

     

     

    816

     

    Marketable debt securities - non-current

     

    320

     

     

     

    364

     

    Cash, cash equivalents and marketable debt securities

    $

    11,179

     

     

    $

    12,644

     

    Short-term debt obligations

     

    (2,046

    )

     

     

    (3,119

    )

    Long-term debt

     

    (47,603

    )

     

     

    (36,653

    )

    Net debt position

    $

    (38,470

    )

     

    $

    (27,128

    )

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250206992763/en/

    For more information, contact:

    Media Relations: [email protected]

    Investor Relations: [email protected]

    Get the next $BMY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BMY

    DatePrice TargetRatingAnalyst
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    4/22/2025Overweight
    Piper Sandler
    12/16/2024$70.00Hold → Buy
    Jefferies
    12/10/2024$63.00Neutral
    BofA Securities
    11/15/2024Peer Perform
    Wolfe Research
    11/13/2024Neutral → Outperform
    Daiwa Securities
    11/12/2024$73.00Market Perform → Outperform
    Leerink Partners
    10/25/2024$75.00 → $55.00Buy → Neutral
    Citigroup
    More analyst ratings

    $BMY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/21/25 7:09:34 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $100,000 worth of shares (1,823 units at $54.84), increasing direct ownership by 3% to 63,932 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      2/19/25 7:19:54 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia

      Cobenfy as an adjunctive treatment to atypical antipsychotics did not reach the threshold for a statistically significant difference compared to placebo with an atypical antipsychotic for the primary endpoint of the change from baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) total score Treatment with Cobenfy and an atypical antipsychotic showed a numerical improvement compared to treatment with placebo and an atypical antipsychotic Cobenfy's safety and tolerability profile as an adjunctive therapy was consistent with previous monotherapy trials Bristol Myers Squibb (NYSE:BMY) today announced topline results from the Phase 3 ARISE trial evaluating the efficacy and

      4/22/25 4:15:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

      For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

      9/26/24 6:42:20 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 14, 2024 - FDA Roundup: June 14, 2024

      For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

      6/14/24 3:54:45 PM ET
      $MMSI
      $BMY
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • March 8, 2024 - FDA Roundup: March 8, 2024

      For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

      3/8/24 3:26:46 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by EVP, Chief Commercial Officer Lenkowsky Adam

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      5/5/25 5:41:48 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/29/25 6:14:13 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Glob. Prod. Dev. & Supply Shanahan Karin converted options into 3,306 shares and covered exercise/tax liability with 1,692 shares, increasing direct ownership by 13% to 13,797 units (SEC Form 4)

      4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

      4/3/25 5:15:32 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/23 11:12:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bristol-Myers Squibb Company (Amendment)

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/9/22 3:33:30 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - BRISTOL MYERS SQUIBB CO (0000014272) (Subject)

      2/10/21 10:39:37 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Financials

    Live finance-specific insights

    See more
    • Bristol Myers Squibb Reports First Quarter Financial Results for 2025

      Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution   First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) GAAP EPS was $1.20 and non-GAAP EPS was $1.80 Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 billion; Increasing non-GAAP EPS range to $6.70 to $7.00 Bristol Myers Squibb (NYSE:BMY) today reports results for the first quarter of 2025. "Our strong execution in the first quarter drove continued momentum across our Growth Portfolio and meaningful progress in the pipeline," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Sq

      4/24/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025

      Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2025 on Thursday, April 24, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company wh

      3/13/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Announces Dividend

      Bristol Myers Squibb (NYSE:BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-two cents ($0.62) per share on the $0.10 par value common stock of the company. The dividend is payable on May 1, 2025, to stockholders of record at the close of business on April 4, 2025. In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 2, 2025, to stockholders of record at the close of business on May 6, 2025. About Bristol Myers Squibb Company Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and d

      3/3/25 4:16:00 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    Leadership Updates

    Live Leadership Updates

    See more
    • Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer

      Gallman's Appointment is Effective Immediately Sandra Leung, Executive Vice President, General Counsel Retires After 33 Years of Service Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer, effective immediately. Gallman succeeds Sandra (Sandy) Leung, who has chosen to retire after an extraordinary 33-year career at the company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250506937441/en/Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer Gallman, an accomplished leade

      5/6/25 6:59:00 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer

      Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Karen Lewis has joined the company as Chief People Officer. She joins Cardurion with more than 25 years of experience in human resources helping to build organizations and develop programs that support companies at various stages of growth. She most recently was Chief People Officer at Apellis Pharmaceuticals (NASDAQ:APLS) during a period of rapid growth, and previously held leadership roles in human resources at Biogen (NASDAQ:BIIB) and Bristol-Myers Squibb (NYSE:BMY). "We're delighted

      3/20/25 8:00:00 AM ET
      $APLS
      $BIIB
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

      LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14. Kozmina will lead global human resources, serve on the Executive Leadership Team, and report to Vladimir Makatsaria, Chief Executive Officer. "Natalia has a deep background in the medtech and life sciences sectors and is a proven enterprise and executive leader in human resources management," Makatsaria said. "I look forward to collaborating with Natalia to further strengthen our organizational culture and build a thriving environment at LivaNova." Kozmina most recently served as Executive Vice

      1/6/25 9:00:00 AM ET
      $ABT
      $BMY
      $IRM
      $LIVN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Real Estate Investment Trusts
      Real Estate

    $BMY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Bristol-Myers with a new price target

      Cantor Fitzgerald initiated coverage of Bristol-Myers with a rating of Neutral and set a new price target of $55.00

      4/22/25 8:00:39 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Bristol-Myers

      Piper Sandler initiated coverage of Bristol-Myers with a rating of Overweight

      4/22/25 7:30:03 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers upgraded by Jefferies with a new price target

      Jefferies upgraded Bristol-Myers from Hold to Buy and set a new price target of $70.00

      12/16/24 6:45:40 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BMY
    SEC Filings

    See more
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      5/7/25 5:04:09 PM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Bristol-Myers Squibb Company

      10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 11:45:34 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)

      4/24/25 7:11:41 AM ET
      $BMY
      Biotechnology: Pharmaceutical Preparations
      Health Care